![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
HN Doods, W Wienen, M Entzeroth, K Rudolf, W Eberlein, W Engel and HA Wieland
Dr. Karl Thomae GmbH, Biberach, Germany.
The present study was undertaken to investigate the in vitro and in vivo pharmacological profile of the novel, nonpeptide neuropeptide Y (NPY) Y1-selective antagonist, BIBP 3226 [(R)-N2-(diphenylacetyl)-N-[(4- hydroxyphenyl)methyl]-D-arginine-am ide], and a recently described peptidic structure [Ile-Glu-Pro-Orn-Tyr-Arg-Leu-Arg-Tyr-NH2, cyclic (2,4'), (2',4)-diamide]. BIBP 3226 antagonized the NPY Y1 receptor- mediated decrease in the twitch response in the rabbit vas deferens preparation with a pKb value of 6.98 +/- 0.06 (n = 16). It showed no affinity (EC50 > 1 microM) for NPY Y2 receptors in the rat vas deferens. NPY-induced increases in perfusion pressure in the isolated perfused rat kidney and rabbit ear preparations were antagonized with IC50 values of 26.8 +/- 4.5 (n = 4) and 214 +/- 30 nM (n = 4), respectively. The NPY-mediated potentiation of the noradrenaline elicited increase in perfusion pressure in the rat mesenteric bed was antagonized with an IC50 value of 976 (542-1760) nM. The NPY-induced increase in blood pressure in the pithed rat was inhibited by BIBP 3226 dose-dependently (ED50 = 0.11 +/- 0.03 mg/kg i.v.), whereas no effect of BIBP 3226 (1 mg/kg i.v.) was observed for the noradrenaline-, angiotensin-, endothelin- or vasopressin-induced pressor response. The data presented demonstrate that BIBP 3226 is a competitive and NPY Y1- selective antagonist. The peptidic compound proved to possess high potency for NPY Y1 receptors, but showed both agonistic as well as antagonistic properties.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Misra, K. S. Murthy, H. Zhou, and J. R. Grider Coexpression of Y1, Y2, and Y4 Receptors in Smooth Muscle Coupled to Distinct Signaling Pathways J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1154 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Stephens, A. R. Saad, L. A. T. Bennett, W. A. Kosiba, and J. M. Johnson Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1404 - H1409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Raposinho, T. Pedrazzini, R. B. White, R. D. Palmiter, and M. L. Aubert Chronic Neuropeptide Y Infusion into the Lateral Ventricle Induces Sustained Feeding and Obesity in Mice Lacking Either Npy1r or Npy5r Expression Endocrinology, January 1, 2004; 145(1): 304 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-Q. Sun, S. C. Baraban, D. A. Prince, and J. R. Huguenard Target-Specific Neuropeptide Y-Ergic Synaptic Inhibition and Its Network Consequences within the Mammalian Thalamus J. Neurosci., October 22, 2003; 23(29): 9639 - 9649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, E. W. Lee, H. Ji, and Z. Zukowska Neuropeptide Y-Induced Acceleration of Postangioplasty Occlusion of Rat Carotid Artery Arterioscler. Thromb. Vasc. Biol., July 1, 2003; 23(7): 1204 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mullins, D. Kirby, J. Hwa, M. Guzzi, J. Rivier, and E. Parker Identification of Potent and Selective Neuropeptide Y Y1 Receptor Agonists with Orexigenic Activity in Vivo Mol. Pharmacol., September 1, 2001; 60(3): 534 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michalkiewicz, T. Michalkiewicz, D. L. Kreulen, and S. J. McDougall Increased blood pressure responses in neuropeptide Y transgenic rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2001; 281(2): R417 - R426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Y. Ho, A. G. Beck-Sickinger, and W. F. Colmers Neuropeptide Y5 Receptors Reduce Synaptic Excitation in Proximal Subiculum, But Not Epileptiform Activity in Rat Hippocampal Slices J Neurophysiol, February 1, 2000; 83(2): 723 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Raposinho, P. Broqua, D. D. Pierroz, A. Hayward, Y. Dumont, R. Quirion, J.-L. Junien, and M. L. Aubert Evidence That the Inhibition of Luteinizing Hormone Secretion Exerted by Central Administration of Neuropeptide Y (NPY) in the Rat Is Predominantly Mediated by the NPY-Y5 Receptor Subtype Endocrinology, September 1, 1999; 140(9): 4046 - 4055. [Abstract] [Full Text]
|
|
|
|
|
|
V. Cortés, M.V. Donoso, N. Brown, R. Fanjul, C. López, A. Fournier, and J. P. Huidobro-Toro Synergism between Neuropeptide Y and Norepinephrine Highlights Sympathetic Cotransmission: Studies in Rat Arterial Mesenteric Bed with Neuropeptide Y, Analogs, and BIBP 3226 J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1313 - 1322. [Abstract] [Full Text]
|
|
|
|
|
|
L. Sun and R. J. Miller Multiple Neuropeptide Y Receptors Regulate K+ and Ca2+ Channels in Acutely Isolated Neurons From the Rat Arcuate Nucleus J Neurophysiol, March 1, 1999; 81(3): 1391 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-O. Carlsson, A. Andersson, and L. Jansson Influence of age, hyperglycemia, leptin, and NPY on islet blood flow in obese-hyperglycemic mice Am J Physiol Endocrinol Metab, October 1, 1998; 275(4): E594 - E601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dumont, A. Fournier, and R. Quirion Expression and Characterization of the Neuropeptide Y Y5 Receptor Subtype in the Rat Brain J. Neurosci., August 1, 1998; 18(15): 5565 - 5574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Gribkoff, R. L. Pieschl, T. A. Wisialowski, A. N. van den Pol, and F. D. Yocca Phase Shifting of Circadian Rhythms and Depression of Neuronal Activity in the Rat Suprachiasmatic Nucleus by Neuropeptide Y: Mediation by Different Receptor Subtypes J. Neurosci., April 15, 1998; 18(8): 3014 - 3022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sun, L. H. Philipson, and R. J. Miller Regulation of K+ and Ca++ Channels by a Family of Neuropeptide Y Receptors J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 625 - 632. [Abstract] [Full Text]
|
|
|
|
|
|
S. Han, C.-L. Yang, X. Chen, L. Naes, B. F. Cox, and T. Westfall Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction Am J Physiol Heart Circ Physiol, January 1, 1998; 274(1): H290 - H294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.V. Donoso, M. Steiner, and J. P. Huidobro-Toro BIBP 3226, Suramin and Prazosin Identify Neuropeptide Y, Adenosine 5'-Triphosphate and Noradrenaline as Sympathetic Cotransmitters in the Rat Arterial Mesenteric Bed J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 691 - 698. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Leupen, L. M. Besecke, and J. E. Levine Neuropeptide Y Y1-Receptor Stimulation Is Required for Physiological Amplification of Preovulatory Luteinizing Hormone Surges Endocrinology, July 1, 1997; 138(7): 2735 - 2739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Rhim, G. A. Kinney, P. J. Emmerson, and R. J. Miller Regulation of Neurotransmission in the Arcuate Nucleus of the Rat by Different Neuropeptide Y Receptors J. Neurosci., May 1, 1997; 17(9): 2980 - 2989. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
